Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Covington
UBS
Moodys
Accenture
McKinsey
Daiichi Sankyo
Queensland Health
Cantor Fitzgerald
Medtronic

Generated: December 10, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,362,178

« Back to Dashboard

Which drugs does patent 6,362,178 protect, and when does it expire?


Patent 6,362,178 protects STAXYN and LEVITRA and is included in two NDAs. There have been zero Paragraph IV challenges on Staxyn and Levitra

This patent has eighty-four patent family members in forty-six countries.

Summary for Patent: 6,362,178

Title: 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
Abstract:The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
Inventor(s): Niewohner; Ulrich (Wermelskirchen, DE), Es-Sayed; Mazen (Langenfeld, DE), Haning; Helmut (Wuppertal, DE), Schenke; Thomas (Gladbach, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Keldenich; Jorg (Wuppertal, DE), Bischoff; Erwin (Wuppertal, DE), Perzborn; Elisabeth (Wuppertal, DE), Dembowsky; Klaus (Boston, MA), Serno; Peter (Gladbach, DE), Nowakowski; Marc (Wuppertal, DE)
Assignee: Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:09/554,162
Patent Claim Types:
see list of patent claims
Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Bayer HlthcareSTAXYNvardenafil hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL200179-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF ERECTILE DYSFUNCTION
Bayer HlthcareLEVITRAvardenafil hydrochlorideTABLET;ORAL021400-003Aug 19, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeYYERECTILE DYSFUNCTION
Bayer HlthcareLEVITRAvardenafil hydrochlorideTABLET;ORAL021400-001Aug 19, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeYYERECTILE DYSFUNCTION
Bayer HlthcareLEVITRAvardenafil hydrochlorideTABLET;ORAL021400-002Aug 19, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeYYERECTILE DYSFUNCTION
Bayer HlthcareLEVITRAvardenafil hydrochlorideTABLET;ORAL021400-004Aug 19, 2003ABRXYesYes► Subscribe► Subscribe► SubscribeYYERECTILE DYSFUNCTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,362,178

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany197 50 085Nov 12, 1997
Germany198 12 462Mar 23, 1998
Germany198 40 289Sep 04, 1998
PCT Information
PCT FiledOctober 31, 1998PCT Application Number:PCT/EP98/06910
PCT Publication Date:May 20, 1999PCT Publication Number: WO99/24433

Non-Orange Book Patents for Patent: 6,362,178

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,566,360 2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors► Subscribe
7,696,2062-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
7,314,8712-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension► Subscribe
7,704,9992-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
7,122,5402-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
6,890,922 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,362,178

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Colombia4980861► Subscribe
Czech Republic20001759► Subscribe
Czech Republic301911► Subscribe
Germany19750085► Subscribe
Germany19812462► Subscribe
Germany19840289► Subscribe
Germany19881732► Subscribe
Germany59803108► Subscribe
Denmark200000766► Subscribe
Denmark176852► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Medtronic
Mallinckrodt
Julphar
Healthtrust
Accenture
Daiichi Sankyo
Chinese Patent Office
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot